Dr. Richard Roden is a professor in the Departments of pathology, gynecology and obstetrics, and oncology at the Johns Hopkins University School of Medicine. He also co-leads the Johns Hopkins Kimmel Cancer Center's Cancer Prevention and Control Program. His research focuses on approaches to prevent and treat cervical and ovarian cancer.
Dr. Roden’s team is currently engaged in research to prevent cervical cancer through the development of a minor capsid antigen L2-based vaccine that is active against all oncogenic types of human papillomavirus (HPV). He is also working on vaccines to treat HPV infections. The team is also focused on identifying novel tumor antigens of significance in the biology of ovarian cancer that are applicable as biomarkers for early detection or targets for immunotherapy. In addition, his team has studied proteasome inhibitors as an innovative approach for treating gynecologic cancer and built tissue banks to enable research and ovarian cancer genome sequencing.
He holds a B.Sc. in biochemistry from Bristol University and a Ph.D. in biochemistry from the University of Cambridge, UK. Following a fellowship and a position as visiting associate at National Cancer Institute in Bethesda, Maryland, he joined the faculty of Johns Hopkins in 1998.